StockData
Cue Biopharma, Inc. logo

Cue Biopharma, Inc. (CUE) stock

CUENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 8/30
$4.76+1.93 (+68.20%)

Close on Nov 18, 2026Market cap $34.58MP/E –Yield –

Cue Biopharma operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Cue Biopharma's operating income for the twelve months ending Jun 30, 2026 was -$98.67M. For fiscal 2025 it was -$26.55M. The highest annual figure on record is -$23.23M in fiscal 2017.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$26.55M–
FY2024Dec 31, 2024-$41.50M–
FY2023Dec 31, 2023-$52.15M–
FY2022Dec 31, 2022-$53.23M–
FY2021Dec 31, 2021-$43.71M–
FY2020Dec 31, 2020-$45.04M–
FY2019Dec 31, 2019-$36.77M–
FY2018Dec 31, 2018-$38.70M–
FY2017Dec 31, 2017-$23.23M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$87.70M–
Q1 FY2026Mar 31, 2026-$5.35M–
Q4 FY2025Dec 31, 2025$1.98M–
Q3 FY2025Sep 30, 2025-$7.60M–
Q2 FY2025Jun 30, 2025-$8.64M–
Q1 FY2025Mar 31, 2025-$12.30M–
Q4 FY2024Dec 31, 2024-$9.63M–
Q3 FY2024Sep 30, 2024-$8.82M–
Q2 FY2024Jun 30, 2024-$10.38M–
Q1 FY2024Mar 31, 2024-$12.67M–
Q4 FY2023Dec 31, 2023-$13.83M–
Q3 FY2023Sep 30, 2023-$11.42M–
Q2 FY2023Jun 30, 2023-$13.52M–
Q1 FY2023Mar 31, 2023-$13.38M–
Q4 FY2022Dec 31, 2022-$14.87M–
Q3 FY2022Sep 30, 2022-$11.03M–
Q2 FY2022Jun 30, 2022-$13.09M–
Q1 FY2022Mar 31, 2022-$14.24M–
Q4 FY2021Dec 31, 2021-$7.89M–
Q3 FY2021Sep 30, 2021-$13.02M–
Q2 FY2021Jun 30, 2021-$10.30M–
Q1 FY2021Mar 31, 2021-$12.52M–
Q4 FY2020Dec 31, 2020-$10.97M–
Q3 FY2020Sep 30, 2020-$10.13M–
Q2 FY2020Jun 30, 2020-$10.94M–
Q1 FY2020Mar 31, 2020-$13.00M–
Q4 FY2019Dec 31, 2019-$9.02M–
Q3 FY2019Sep 30, 2019-$7.09M–
Q2 FY2019Jun 30, 2019-$9.23M–
Q1 FY2019Mar 31, 2019-$11.43M–
Q4 FY2018Dec 31, 2018-$10.97M–
Q3 FY2018Sep 30, 2018-$12.76M–
Q2 FY2018Jun 30, 2018-$7.47M–
Q1 FY2018Mar 31, 2018-$7.52M–
Q4 FY2017Dec 31, 2017-$10.44M–
Q3 FY2017Sep 30, 2017-$5.03M–
Q2 FY2017Jun 30, 2017-$4.41M–
Q1 FY2017Mar 31, 2017-$3.35M–

More Cue Biopharma figures

See a number that looks wrong?